Urological Research

, Volume 24, Issue 3, pp 129–134 | Cite as

Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle

II. Effect of various PDE inhibitors on smooth muscle tone and cyclic nucleotide levels in vitro
  • M. C. Truss
  • S. Ückert
  • C. G. Stief
  • W. G. Forssmann
  • U. Jonas
Original Paper

Abstract

Phosphodiesterases (PDEs) regulate intracellular cyclic nucleotide metabolism and, thus, contraction and relaxation of smooth musculature. The aim of the present study was to evaluate the functional effects of isoenzyme-selective inhibitors and their effects on cyclic nucleotide levels in the human detrusor smooth muscle. In addition, the functional relevance of the cAMP versus the cGMP pathways in the regulation of the detrusor smooth muscle tone was assessed. Relaxant responses to various PDE inhibitors, forskolin and sodium nitroprusside (SNP) were investigated in vitro using a standard organ bath setup. Cyclic nucleotide levels were measured after incubation with the same substances using cAMP and cGMP radioimmunoassays (RIAs). Significant relaxant responses were only induced by non-selective PDE inhibition, the PDE I inhibitor vinpocetine and the adenylate cyclase activator forskolin. Relaxant responses to these substances were paralleled by increases in cyclic nucleotide levels. Our data suggest that the cAMP pathway and calcium/calmodulin-stimulated PDE (PDE I) may be of functional importance in the regulation of the human detrusor smooth muscle tone in vitro.

Key words

Phosphodiesterase Detrusor cAMP cGMP 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Arnold JM (1993) The role of phosphodiesterase inhibitors in heart failure. Pharmacol Ther 57:161Google Scholar
  2. 2.
    Beavo J (1990) Multiple phosphodiesterase isoenzymes: back-ground, nomenclature and implications. In: Beavo J, Houslay HM (eds) Cyclic nucleotide phosphodiesterases: structure, regulation and drug action. Wiley, Chichester, p 3Google Scholar
  3. 3.
    Conti M, Setnikar I (1975) Flavoxate, a potent phosphodiesterase inhibitor. Arch Int Pharmacodyn 213:186Google Scholar
  4. 4.
    Hagiwara M, Endo T, Hidaka H (1984) Effects of vinpocetine on cyclic nucleotide metabolism in vascular smooth muscle. Biochem Pharmacol 33(3):453Google Scholar
  5. 5.
    Hardman JG (1984) Cyclic nucleotides and regulation of vascular smooth muscle. J Cardiovasc Pharmacol 6:639Google Scholar
  6. 6.
    Lincoln TM (1989) Cyclic CMP and mechanisms of vasodilation. Pharmacol Ther 41:479Google Scholar
  7. 7.
    Lowry OH, Rosebrough H, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:165Google Scholar
  8. 8.
    Morita T, Tsujii T, Dokita S (1992) Regional difference in functional roles of cAMP and cGMP in lower urinary tract smooth muscle contractility. Urol Int 49:191Google Scholar
  9. 9.
    Nicholson CD, Shahid M (1994) Inhibitors of cyclic nucleotide phosphodiesterase isoenzymes — their potential utility in the therapy of asthma. Pulm Pharmacol 7:1Google Scholar
  10. 10.
    Nicholson CD, Challiss RA, Shahid M (1991) Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. Trends Pharmacol Sci 12:19–27Google Scholar
  11. 11.
    Nosálová V, Machová J, Babulová A (1993) Protective action of vinpocetine against experimentally induced gastric damage in rats. Arzneimittel forschung 43(II):891Google Scholar
  12. 12.
    Persson K, Anderson KE (1992) Nitric oxide and relaxation of pig lower urinary tract. Br J Pharmacol 106:416Google Scholar
  13. 13.
    Persson K, Igawa Y, Mattiasson A, Andersson KE (1992) Effects of inhibition of the l-arginine/nitric oxide pathway in the rat lower urinary tract in vivo and in vitro. Br J Pharmacol 107:178Google Scholar
  14. 14.
    Pharmacia (1991) Dridase (oxybutynin) product information. Pharmacia, Erlangen, 49Google Scholar
  15. 15.
    Schoeffter P, Lugnier C, Demesy WF, Stoclet JC (1987) Role of cyclic AMP- and cyclic GMP-phosphodiesterases in the control of cyclic nucleotide levels and smooth muscle tone in rat isolated aorta. A study with selective inhibitors. Biochem Pharmacol 36:3965Google Scholar
  16. 16.
    Vegesna RV, Diamond J (1983) Comparison of the effects of forskolin and isoproterenol on cyclic AMP levels and tension in bovine coronary artery. Can J Physiol Pharmacol 61:1202Google Scholar
  17. 17.
    Vegesna RV, Diamond J (1986) Elevation of cyclic AMP by prostacyclin is accompanied by relaxation of bovine coronary arteries and contraction of rabbit aortic rings. Eur J Pharmacol 128:25Google Scholar
  18. 18.
    Zhou HL, Torphy TJ (1991) Relationship between cyclic guanosine monophosphate accumulation and relaxation of canine trachealis induced by nitrovasodilators. J Pharmacol Exp Ther 258:972Google Scholar

Copyright information

© Springer-Verlag 1996

Authors and Affiliations

  • M. C. Truss
    • 1
    • 2
  • S. Ückert
    • 1
    • 2
  • C. G. Stief
    • 1
  • W. G. Forssmann
    • 1
  • U. Jonas
    • 1
  1. 1.Department of UrologyHannover Medical SchoolHannoverGermany
  2. 2.Lower Saxony Institute for Peptide ResearchGermany

Personalised recommendations